Acadia Pharmaceuticals (ACAD) Change in Account Payables (2010 - 2026)

Acadia Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 29.43% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at -$5.8 million (down 372.84% YoY), while the FY2025 annual figure was -$5.3 million, down 291.49% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.3 million, up from -$10.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $5.2 million in Q4 2023, with the low at -$10.8 million in Q4 2025.
• The 5-year median for Change in Account Payables is $1.4 million (2023), against an average of $315882.4.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables soared 993.26% in 2022, then sank 275.35% in 2025.
• Acadia Pharmaceuticals' Change in Account Payables stood at $2.7 million in 2022, then soared by 91.12% to $5.2 million in 2023, then tumbled by 155.21% to -$2.9 million in 2024, then tumbled by 275.35% to -$10.8 million in 2025, then surged by 112.38% to $1.3 million in 2026.
• Business Quant data shows ACAD's Change in Account Payables at $1.3 million in Q1 2026, -$10.8 million in Q4 2025, and $1.6 million in Q3 2025.